Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | COSMOS: key updates for MOR208 plus venetoclax for R/R CLL

Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, discusses the results of the COSMOS trial (NCT02639910), investigating anti-CD19 MOR208 in combination with venetoclax in chronic lymphocytic leukemia (CLL) patients who discontinued BTK inhibitor therapy. This revealed encouraging activity, with acceptable safety and tolerability.